All Stories

  1. Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis

    Article • Expert Opinion on Drug Safety, May 2019, Taylor & Francis

    Dr GIUSEPPE CABIBBO

  2. Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?

    Article • Liver International, July 2018, Wiley

    Dr GIUSEPPE CABIBBO

  3. Metabolic disorders across hepatocellular carcinoma in Italy

    Article • Liver International, June 2018, Wiley

    Dr GIUSEPPE CABIBBO, Professor Edoardo G. Giannini, Fabio Marra

  4. Increased incidence or recurrence of hepatocellular carcinoma in hepatitis C virus cirrhotic patients treated with direct-acting antivirals: myth or fact?

    Article • Expert Review of Anticancer Therapy, February 2018, Taylor & Francis

    Dr GIUSEPPE CABIBBO

  5. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study

    Article • Alimentary Pharmacology & Therapeutics, August 2017, Wiley

    Dr GIUSEPPE CABIBBO, Professor Giovanni Squadrito

  6. Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review

    Article • Journal of Hepatocellular Carcinoma, July 2017, Dove Medical Press

    Professor Rodolfo Sacco, Dr GIUSEPPE CABIBBO

  7. Report from European Association for the Study of the Liver: HCC Summit, Geneva, Switzerland, 2–5 February 2017

    Article • Future Oncology, June 2017, Future Medicine

    Professor Rodolfo Sacco, Dr GIUSEPPE CABIBBO

  8. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response

    Article • Liver International, May 2017, Wiley

    Dr GIUSEPPE CABIBBO

  9. A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma

    Article • Liver International, February 2017, Wiley

    Dr GIUSEPPE CABIBBO, Professor Edoardo G. Giannini

  10. The calm before the storm: a report from the International Liver Cancer Association Congress 2015 – part 2

    Article • Future Oncology, February 2016, Future Medicine

    Professor Rodolfo Sacco, Dr GIUSEPPE CABIBBO

  11. The calm before the storm: a report from the International Liver Cancer Association Congress 2015 – part 1

    Article • Future Oncology, February 2016, Future Medicine

    Professor Rodolfo Sacco, Dr GIUSEPPE CABIBBO

  12. Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma

    Article • The American Journal of Gastroenterology, January 2016, Nature

    Dr GIUSEPPE CABIBBO

  13. Refining prognosis after trans-arterial chemo-embolization for hepatocellular carcinoma

    Article • Liver International, December 2015, Wiley

    Dr GIUSEPPE CABIBBO

  14. Curative therapies for hepatocellular carcinoma: an update and perspectives

    Article • Expert Review of Anticancer Therapy, December 2015, Taylor & Francis

    Dr GIUSEPPE CABIBBO, Professor Roberto Eggenhoffner

  15. Recurrence of hepatocellular carcinoma after liver transplantation: an update

    Article • Future Oncology, November 2015, Future Medicine

    Dr GIUSEPPE CABIBBO

  16. Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor

    Article • Liver Transplantation, September 2015, Wiley

    Dr GIUSEPPE CABIBBO

  17. Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice

    Article • Digestive Diseases, September 2015, Karger Publishers

    Dr GIUSEPPE CABIBBO

  18. Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?

    Article • Future Oncology, September 2015, Future Medicine

    Dr GIUSEPPE CABIBBO

  19. Computed tomography of bowel obstruction: tricks of the trade

    Article • Expert Review of Gastroenterology & Hepatology, June 2015, Taylor & Francis

    Dr GIUSEPPE CABIBBO

  20. Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis

    Article • Digestive and Liver Disease, April 2015, Elsevier

    Dr GIUSEPPE CABIBBO

  21. Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib

    Article • Hepatology, March 2015, Wiley

    Dr GIUSEPPE CABIBBO

  22. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study

    Article • Journal of Hepatology, March 2015, Elsevier

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  23. Reply

    Article • Hepatology, January 2015, Wiley

    Dr GIUSEPPE CABIBBO

  24. Ultrasound-guided ablation for hepatocellular carcinoma: time for a reappraisal?

    Article • Expert Review of Anticancer Therapy, January 2015, Taylor & Francis

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  25. Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C

    Article • Digestive and Liver Disease, October 2014, Elsevier

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  26. Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C

    Article • Journal of Hepatology, September 2014, Elsevier

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  27. European Association for the Study of the Liver Hepatocellular Carcinoma summit 2014: old questions, new (or few) answers?

    Article • Future Oncology, August 2014, Future Medicine

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  28. Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma

    Article • Journal of Hepatology, August 2014, Elsevier

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  29. Transarterial chemoembolization and sorafenib in hepatocellular carcinoma

    Article • Expert Review of Anticancer Therapy, May 2014, Taylor & Francis

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  30. Focal lesions in cirrhotic liver: what else beyond hepatocellular carcinoma?

    Article • Diagnostic and Interventional Radiology, May 2014, AVES Publishing Co.

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  31. EASL HCC summit: liver cancer management

    Article • Future Oncology, May 2014, Future Medicine

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  32. Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection

    Article • Clinical Gastroenterology and Hepatology, May 2014, Elsevier

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  33. Determinants of alpha‐fetoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use

    Article • Cancer, April 2014, Wiley

    PhD Giuseppe Cabibbo, Professor Edoardo G. Giannini, Dr GIUSEPPE CABIBBO

  34. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C

    Article • Hepatology, April 2014, Wolters Kluwer Health

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  35. Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results

    Article • La radiologia medica, December 2013, Springer Science + Business Media

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  36. Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?

    Article • Expert Review of Anticancer Therapy, December 2013, Taylor & Francis

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  37. Faculty of 1000 evaluation for Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma.

    Article • October 2013, Faculty of 1000, Ltd.

    Dr GIUSEPPE CABIBBO

  38. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C

    Article • Journal of Hepatology, October 2013, Elsevier

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  39. NT Pro BNP Plasma Level and Atrial Volume Are Linked to the Severity of Liver Cirrhosis

    Article • PLoS ONE, August 2013, PLOS

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  40. Survival of Patients with Hepatocellular Carcinoma (HCC) Treated by Percutaneous Radio-Frequency Ablation (RFA) Is Affected by Complete Radiological Response

    Article • PLoS ONE, July 2013, PLOS

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  41. Rise and fall of HCV‐related hepatocellular carcinoma in Italy: a long‐term survey from the ITA.LI.CA centres

    Article • Liver International, June 2013, Wiley

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  42. Assessment of treatment response in hepatocellular carcinoma: a review of the literature

    Article • Future Oncology, June 2013, Future Medicine

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  43. Faculty Opinions recommendation of Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study.

    Article • May 2013, F1000Research

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  44. Treatment of hepatocellular carcinoma: present and future

    Article • Expert Review of Anticancer Therapy, April 2013, Taylor & Francis

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  45. Faculty Opinions recommendation of Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study.

    Article • February 2013, F1000Research

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  46. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma

    Article • Hepatology, February 2013, Wolters Kluwer Health

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  47. Faculty Opinions recommendation of Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection.

    Article • October 2012, F1000Research

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  48. Causes of and Prevention Strategies for Hepatocellular Carcinoma

    Article • Seminars in Oncology, August 2012, Elsevier

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  49. Faculty Opinions recommendation of Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease.

    Article • July 2012, F1000Research

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  50. Imaging findings of liver resection using a bipolar radiofrequency electrosurgical device—Initial observations

    Article • European Journal of Radiology, April 2012, Elsevier

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  51. Reply:

    Article • Hepatology, March 2012, Wiley

    Dr GIUSEPPE CABIBBO

  52. Faculty Opinions recommendation of Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.

    Article • January 2012, F1000Research

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  53. Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study

    Article • World Journal of Hepatology, January 2012, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  54. Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy

    Article • Hepatology, December 2011, Wolters Kluwer Health

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  55. Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib

    Article • Expert Review of Anticancer Therapy, December 2011, Taylor & Francis

    Dr GIUSEPPE CABIBBO

  56. Should cirrhosis change our attitude towards treating non‐hepatic cancer?

    Article • Liver International, August 2011, Wiley

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  57. Update on new approaches in the management of hepatocellular carcinoma

    Article • Hepatic Medicine Evidence and Research, November 2010, Taylor & Francis

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  58. Cost analysis of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma

    Article • Digestive and Liver Disease, October 2010, Elsevier

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  59. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma

    Article • Hepatology, December 2009, Wolters Kluwer Health

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  60. Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis

    Article • Journal of Hepatology, October 2009, Elsevier

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  61. Prognostic scores for hepatocellular carcinoma: none is the winner

    Article • Liver International, March 2009, Wiley

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  62. Multimodal approaches to the treatment of hepatocellular carcinoma

    Article • Nature Reviews Gastroenterology & Hepatology, February 2009, Springer Science + Business Media

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  63. Needle track seeding following percutaneous procedures for hepatocellular carcinoma

    Article • World Journal of Hepatology, January 2009, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  64. Hepatocellular Cancer: Optimal Strategies for Screening and Surveillance

    Article • Digestive Diseases, January 2009, Karger Publishers

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  65. Meta-Analysis of the Placebo Rates of Clinical Relapse and Severe Endoscopic Recurrence in Postoperative Crohn's Disease

    Article • Gastroenterology, November 2008, Elsevier

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  66. Long-Term Course of Chronic Hepatitis C in Children: From Viral Clearance to End-Stage Liver Disease

    Article • Gastroenterology, June 2008, Elsevier

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  67. The impact of radiotherapy on survival in resectable gastric carcinoma: A meta-analysis of literature data

    Article • Cancer Treatment Reviews, December 2007, Elsevier

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  68. Mortality in patients with hepatocellular carcinoma predicted by six scoring systems: None is the winner

    Article • Digestive and Liver Disease, March 2007, Elsevier

    PhD Giuseppe Cabibbo, Dr GIUSEPPE CABIBBO

  69. Treatment of hepatitis C: critical appraisal of the evidence

    Article • Expert Opinion on Pharmacotherapy, March 2005, Informa Healthcare

    Dr GIUSEPPE CABIBBO

  70. Faculty of 1000 evaluation for Multidisciplinary management of hepatocellular carcinoma.

    Article • Faculty of 1000, Ltd.

    Dr GIUSEPPE CABIBBO